$100 Million Funds RSV/hMPV Bivalent Vaccine Candidate

Vicebio Ltd. today announced a $100 million Series B financing led by TCGX and others. Vicebio is developing next-generation vaccines for respiratory viruses utilizing its proprietary Molecular Clamp technology, which was discovered at the University of Queensland (UQ).

The Molecular Clamp technology applies to a wide range of viruses, including Respiratory Syncytial Virus (RSV), Human Metapneumovirus (hMPV), Parainfluenza virus, Influenza, and Coronaviruses, as confirmed by promising preclinical and clinical studies.

Vicebio has recently initiated a Phase I clinical trial with VXB-241, its bivalent vaccine targeting RSV and hMPV. Initial clinical readouts of the Phase 1 study are expected to launch in mid-2025.

This financing will also support the acceleration and expansion further development of Vicebio’s multivalent pipeline, including VXB-251, a trivalent vaccine targeting RSV, hMPV, and Parainfluenza Virus 3, a further valency that addresses a significant remaining medical burden in the elderly.

Cariad Chester, Managing Partner at TCGX, said in a September 23, 2024, press release, “Vicebio has a unique capability to advance vaccine products that simultaneously provide robust immune responses against multiple respiratory pathogens. We look forward to working closely with the team to bring these important vaccines to the market.”

Prof. Paul Young, Daniel Watterson, and Keith Chappell at UQ developed the Molecular Clamp proprietary technology.